# Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant

> **NCT06129734** · PHASE1,PHASE2 · RECRUITING · sponsor: **Benjamin Tomlinson** · enrollment: 20 (estimated)

## Conditions studied

- Myeloid Malignancy
- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT06129734
- **Lead sponsor:** Benjamin Tomlinson
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2026-12
- **Final completion:** 2027-07
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06129734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06129734, "Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06129734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*